Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06475183 · ClinicalTrials.gov registry record · NA
Probiotic Chocolate Study in Multiple Sclerosis
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
NCT06475183: Completed NA study, sponsored by Columbia University.
NCT06475183 is a NA study that has completed, run by Columbia University. The registered enrollment target is 92 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06475183, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
Study Summary
The goal of this study is to assess the effects of probiotics on persons with multiple sclerosis (MS), persons at higher genetic risk for MS (first degree family members of persons with MS), and healthy controls. Participants will be asked to consume probiotic containing chocolates (Bouchard Belgian Dark Chocolate Probiotic Napolitains containing 10 billion CFUs of bifidobacterium longum per day) for 6 weeks. Participants will undergo blood draws before and after the 6 weeks of probiotic containing chocolate and microbial metabolites and immune markers will be compared before and after the probiotics, as well as between groups.
Primary Outcome
percent change in Treg cells from baseline to week 6
Interventions
- DIETARY_SUPPLEMENT Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2024-12-09 |
| Phase | NA |
What the finished NCT06475183 record still lists
NCT06475183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum is the first listed.
NCT06475183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06475183 about?
NCT06475183 is a clinical study titled "Probiotic Chocolate Study in Multiple Sclerosis". The goal of this study is to assess the effects of probiotics on persons with multiple sclerosis (MS), persons at higher genetic risk for MS (first degree family members of persons with MS), and healthy controls. Participants will be asked to consume probiotic containing chocolates (Bouchard Belgian...
What is the current status of trial NCT06475183?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2024-06-01. Estimated completion is 2024-12-09.
What interventions are being tested in trial NCT06475183?
The interventions under investigation include: Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06475183?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06475183's enrollment target sits among peer trials
92 937th of 2000 higher than 1,062 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI